Drug intelligence / Profile preview

EQ-778

Development stage: Unknown
Lead developer: Vedic Lifesciences

Overview

EQ-778 is an investigational agent evaluated for its effect on **upper respiratory tract health** in healthy adults, specifically in the context of upper respiratory tract infection, respiratory syncytial virus (RSV) infection, and pediatric bronchitis. The mechanism of action, active ingredient, and modality (such as small molecule, biologic, or supplement) have not been disclosed in available sources. EQ-778 is the subject of a double-blind, placebo-controlled, randomized clinical trial over 180 days of administration. The primary developer and sponsor is Vedic Lifesciences Pvt. Ltd. Details regarding its pharmacological properties, specific mechanism of action, and regulatory status beyond clinical trial are not available from the retrieved sources[1][3].

Brand names: EQ-778EQ778EQ 778
Other names: EQ-778EQ778EQ 778

Beyond the preview

Go deeper on EQ-778.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EQ-778.

Explore the full profile